Clinical Trials · NCT02020499

Predictive Factors Study

Phase
N/A
Recruitment status
Terminated
Sponsor
Ipsen
Enrollment
5
Start date
Aug 2014
Locations
6 sites, Australia
Primary endpoint
Change in Growth hormone (GH) and insulin-like growth factor-1 (IGF-1) levels from baseline
View Lanreotide compound reference